Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 Long-Term Follow-Up in Melanoma
NCT01559818Phase 2Terminated
- Sponsor
- Immodulon Therapeutics
- Start
- Feb 2012
- Primary completion
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-101 in Malignant Melanoma (MM), sponsored by Immodulon Therapeutics. Started Feb 2012; status: terminated.
02
Drugs
IMM-101
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01559818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559818.